References
- O'Brien SG, Guilhot F, Larson RA, et al Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994–1004.
- Druker B, Guilhot F, O'Brien S, et al Five-year follow-up of imatinib therapy for newly diagnosed chronic myelogenous leukemia in chronic-phase shows sustained responses and high overall survival. N Engl J Med 2006;355:2408–2417.
- Kantarjian H, Sawyers C, Hochhaus A, et al Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645–652.
- Kantarjian HM, Cortes JE, O'Brien S, et al Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood 2004;104:1979–1988.
- Hochhaus A, Druker B, Sawyers C, et al Favorable long-term follow-up results over six years for response, survival and safety with imatinib mesylate therapy in chronic phase chronic myeloid leukemia post failure of interferon-alpha treatment. Blood 2008;111:1039–1043.
- Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1018–1029.
- Gorre ME, Mohammed M, Ellwood K, et al Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876–880.
- Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640–2653.
- Corbin AS, La Rosee P, Stroffregen EP, Druker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003;101:4611–4614.
- O'Hare T, Walters DK, Stoffregen EP, et al In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500–4505.
- Soverini S, Martinelli G, Rosti G, et al ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005;23:4100–4109.
- Branford S, Cross NCP, Hochhaus A, et al Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 2006;20:1925–1930.
- Hughes TP, Deininger MW, Hochhaus A, et al Monitoring CML patients responding to treatment with tyrosine kinase inhibitors – review and recommendations for ‘harmonizing’ current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28–37.
- Baccarani M, Martinelli G, Rosti G, et al Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukaemia. Blood 2004;104:4245–4251.
- Branford S, Fletcher L, Cross NC, et al Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008;112:3330–3338.
- Deininger M. Milestones and monitoring in patients with CML treated with imatinib. Hematology 2008;418–426.
- Pfeifer H, Wassmann B, Pavlova A, et al Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL). Blood 2007;110:727–734.
- de Lavallade H, Apperley JF, Khorashad JS, et al Imatinib for newly diagnosed patients with chronic myeloid leukaemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3308–3309.
- Kantarjian H, Quintas-Cardama A, O'Brien S, et al Importance of early intervention with dasatinib at cytogenetic rather than hematologic resistance to imatinib. Blood 2007;110:314a.